Charles Schwab Investment Management Inc. Grows Stock Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Charles Schwab Investment Management Inc. raised its stake in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) by 1.8% in the fourth quarter, Holdings Channel reports. The institutional investor owned 284,540 shares of the company’s stock after buying an additional 4,963 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Y-mAbs Therapeutics were worth $2,228,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Intech Investment Management LLC purchased a new position in Y-mAbs Therapeutics in the 3rd quarter worth $133,000. FMR LLC raised its stake in Y-mAbs Therapeutics by 23.1% during the third quarter. FMR LLC now owns 36,416 shares of the company’s stock valued at $479,000 after buying an additional 6,822 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Y-mAbs Therapeutics in the 3rd quarter worth approximately $44,000. Caligan Partners LP grew its stake in shares of Y-mAbs Therapeutics by 105.3% in the third quarter. Caligan Partners LP now owns 1,195,253 shares of the company’s stock worth $15,718,000 after acquiring an additional 613,175 shares during the period. Finally, State Street Corp lifted its holdings in shares of Y-mAbs Therapeutics by 50.4% during the 3rd quarter. State Street Corp now owns 1,209,781 shares of the company’s stock valued at $15,909,000 after buying an additional 405,169 shares during the period. Institutional investors own 70.85% of the company’s stock.

Insider Buying and Selling at Y-mAbs Therapeutics

In related news, insider Thomas Gad sold 10,810 shares of the business’s stock in a transaction on Friday, March 7th. The shares were sold at an average price of $5.23, for a total value of $56,536.30. Following the completion of the transaction, the insider now directly owns 202,721 shares in the company, valued at $1,060,230.83. The trade was a 5.06 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 22.50% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages have commented on YMAB. Wedbush restated an “outperform” rating and issued a $23.00 price target on shares of Y-mAbs Therapeutics in a research report on Monday, March 3rd. Bank of America lowered their target price on shares of Y-mAbs Therapeutics from $14.00 to $12.00 and set a “neutral” rating for the company in a report on Wednesday, March 5th. Truist Financial lowered their target price on Y-mAbs Therapeutics from $21.00 to $18.00 and set a “buy” rating for the company in a report on Wednesday, March 5th. Brookline Capital Management started coverage on Y-mAbs Therapeutics in a research report on Thursday, December 5th. They set a “buy” rating and a $17.00 price objective on the stock. Finally, HC Wainwright cut their target price on Y-mAbs Therapeutics from $22.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, March 21st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Y-mAbs Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $18.30.

Y-mAbs Therapeutics Stock Down 3.0 %

Shares of NASDAQ YMAB opened at $4.81 on Friday. Y-mAbs Therapeutics, Inc. has a 52 week low of $4.25 and a 52 week high of $17.78. The firm has a market cap of $217.50 million, a P/E ratio of -8.91 and a beta of 0.65. The business’s 50 day moving average price is $5.58 and its 200 day moving average price is $9.52.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings data on Tuesday, March 4th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.02). Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The business had revenue of $26.50 million during the quarter, compared to analysts’ expectations of $26.70 million. During the same period last year, the company earned ($0.02) earnings per share. As a group, research analysts expect that Y-mAbs Therapeutics, Inc. will post -0.65 earnings per share for the current year.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.